Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.13 billion. The enterprise value is $466.26 million.
Important Dates
The next estimated earnings date is Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 160.84 million shares outstanding. The number of shares has increased by 51.03% in one year.
| Current Share Class | 160.84M |
| Shares Outstanding | 160.84M |
| Shares Change (YoY) | +51.03% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 52.76% |
| Float | 135.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.56 |
| Forward PS | 3.42 |
| PB Ratio | -1.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98
| Current Ratio | 0.98 |
| Quick Ratio | 0.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.63% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -57.13% |
| Revenue Per Employee | $716,557 |
| Profits Per Employee | -$196,953 |
| Employee Count | 952 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 22.58 |
Taxes
In the past 12 months, Novavax has paid $10.88 million in taxes.
| Income Tax | 10.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.33% in the last 52 weeks. The beta is 2.91, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.91 |
| 52-Week Price Change | +44.33% |
| 50-Day Moving Average | 8.14 |
| 200-Day Moving Average | 10.59 |
| Relative Strength Index (RSI) | 35.78 |
| Average Volume (20 Days) | 3,503,560 |
Short Selling Information
The latest short interest is 37.55 million, so 23.35% of the outstanding shares have been sold short.
| Short Interest | 37.55M |
| Short Previous Month | 39.23M |
| Short % of Shares Out | 23.35% |
| Short % of Float | 27.70% |
| Short Ratio (days to cover) | 7.71 |
Income Statement
In the last 12 months, Novavax had revenue of $682.16 million and -$187.50 million in losses. Loss per share was -$1.23.
| Revenue | 682.16M |
| Gross Profit | 112.52M |
| Operating Income | -231.93M |
| Pretax Income | n/a |
| Net Income | -187.50M |
| EBITDA | -183.44M |
| EBIT | -231.93M |
| Loss Per Share | -$1.23 |
Full Income StatementBalance Sheet
The company has $923.12 million in cash and $263.47 million in debt, giving a net cash position of $659.65 million or $4.10 per share.
| Cash & Cash Equivalents | 923.12M |
| Total Debt | 263.47M |
| Net Cash | 659.65M |
| Net Cash Per Share | $4.10 |
| Equity (Book Value) | -623.84M |
| Book Value Per Share | -3.89 |
| Working Capital | -25.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$87.26 million and capital expenditures -$13.06 million, giving a free cash flow of -$100.32 million.
| Operating Cash Flow | -87.26M |
| Capital Expenditures | -13.06M |
| Free Cash Flow | -100.32M |
| FCF Per Share | -$0.62 |
Full Cash Flow StatementMargins
Gross margin is 16.49%, with operating and profit margins of -34.00% and -27.49%.
| Gross Margin | 16.49% |
| Operating Margin | -34.00% |
| Pretax Margin | -25.89% |
| Profit Margin | -27.49% |
| EBITDA Margin | -26.89% |
| EBIT Margin | -34.00% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -51.03% |
| Shareholder Yield | n/a |
| Earnings Yield | -16.65% |
| FCF Yield | -8.91% |
Analyst Forecast
The average price target for Novavax is $17.83, which is 154.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.83 |
| Price Target Difference | 154.71% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -7.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Novavax has an Altman Z-Score of -4.19 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.19 |
| Piotroski F-Score | 3 |